February 8, 2011

Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator

.   .   

In this trial, patients undergoing long-term hemodialysis were randomized to a catheter-locking regimen of heparin (5000 U per milliliter) three times per week or recombinant tissue plasminogen activator (rt-PA) (1 mg in each lumen) instead of heparin once per week. Catheter malfunction occurred almost twice as often in the heparin only group and catheter-related bacteremia occurred less frequently (4.5%) in those assigned to the rt-PA group compared to those assigned to heparin only (13.0%).

Read the accompanying editorial “Tackling the Achilles’ Heel of Hemodialysis”
http://www.nejm.org/doi/full/10.1056/NEJMe1013952

Related Articles:

Hemodialysis, Vascular Access
  • Anonymous

    Correspondence to the NEJM re: Dialysis Catheters and Recombinant Tissue Plasminogen Activator N Engl J Med 2011; 364:1779-1780http://www.nejm.org/doi/full/10.1056/NEJMc1102186